Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIOW) EBITDA (2021 - 2025)

Historic EBITDA for Cardio Diagnostics Holdings (CDIOW) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.

  • Cardio Diagnostics Holdings' EBITDA fell 2147.89% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year increase of 2209.64%. This contributed to the annual value of -$8.4 million for FY2024, which is 1551.16% down from last year.
  • Latest data reveals that Cardio Diagnostics Holdings reported EBITDA of -$1.7 million as of Q3 2025, which was down 2147.89% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Cardio Diagnostics Holdings' EBITDA registered a high of -$397.0 during Q2 2021, and its lowest value of -$4.2 million during Q1 2024.
  • In the last 5 years, Cardio Diagnostics Holdings' EBITDA had a median value of -$1.5 million in 2023 and averaged -$1.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 19812770.78% in 2022, then soared by 6078.54% in 2025.
  • Cardio Diagnostics Holdings' EBITDA (Quarter) stood at -$145321.0 in 2021, then plummeted by 1536.42% to -$2.4 million in 2022, then surged by 35.16% to -$1.5 million in 2023, then grew by 1.66% to -$1.5 million in 2024, then decreased by 12.87% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.6 million during Q1 2025.